Pituitary Tumors-Therapeutics


A Phase 2 Study of Antisense Oligonucleotide Therapy Directed at the GH Receptor Demonstrates Lowering of Serum IGF-I in Patients with Acromegaly
Peter James Trainer, John Newell-Price, John Ayuk, Simon J B Aylwin, Aled Rees, William Drake, Philippe Chanson, Thierry Brue, Susan M. Webb, Carmen Fajardo, Javier Aller, Ann I McCormack, David J Torpy, George Tachas, Lynne Atley and Martin Bidlingmaier


Evaluation of the Effects of LCI699 (Osilodrostat) on Cytochrome P450 Enzymes in Healthy Volunteers: Low Drug-Drug Interaction Potential
Lillian Ting, Anadya Prakash Tripathi, Christelle Darstein, Tracy White and Nicholas Sauter


Determinants of Oral Octreotide Capsules Efficacy in Acromegaly
Shlomo Melmed, Nienke R. Biermasz, Peter J. Trainer, Gary Patou and Asi Haviv


Treatment with High Doses of Pegvisomant in 56 Patients with Acromegaly: Experience from Acrostudy
Aart J. van der Lely, Peter J. Jonsson, Patrick Wilton, Jose Francisco Cara and Ezio Ghigo


Pregnancy Outcomes in Women with Growth Hormone Deficiency Are Not Related to Growth Hormone Treatment during Pregnancy - a Long-Term Observational Study
Greisa Vila, Ann-Charlotte Akerblad, Anders F. Mattsson, Michaela Riedl, Susan M. Webb, Vaclav Hana, Eigil H Nielsen, Beverly M.K. Biller and Anton Luger


Incidence of New Neoplasia in Growth Hormone Treated Adult Patients with Pituitary Deficiency Following Childhood or Adulthood Malignancy
Katarzyna Kryzanowska-Mittermayer, Anton Luger, Dominique Maiter, Ulla Feldt-Rasmussen, Anders F. Mattsson, Ann-Charlotte Akerblad, Nina Camacho-Hubner and Roger Abs